antineoplaston A10
Early clinical developmentAlso known as Antineoplaston A 10, BENZENEACETAMIDE, N-((3S)-2,6-DIOXO-3-PIPERIDINYL)-, BENZENEACETAMIDE, N-(2,6-DIOXO-3-PIPERIDINYL)-, (S)-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Phase II Study of Oral Antineoplastons A10 and AS2-1 in Women With Advanced Breast Cancer
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- Cai H1
- Huang X1
- Li B1
- Li G1
- Liu F1
- Liu T1
- Liu W1
- Lou H1
- Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)1
- Henan Cancer Hospital1
- Hunan Cancer Hospital1
- Sun Yat-sen University Cancer Center1
- Union Hospital1
- Zhongnan Hospital of Wuhan University1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as antineoplaston A10 in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials